Showing posts with label awards. Show all posts
Showing posts with label awards. Show all posts

Wednesday, April 24, 2019

ACOA Invests $2million in Orthpaedic Innovation

Andy Fillmore, Member of Parliament for Halifax, on behalf of the Atlantic Canada Opportunities Agency (ACOA) announced a $2 million investment for a NSHA orthopaedic project on Wednesday April 17th. 

Left to right: Dr. Travis McDonough (CEO & Founder Kinduct), Barbara Campbell (CEO OrthoMX), MP Andy Fillmore (MP for Halifax), Dr. Alex Fuentes (Chief Scientific & Technology Officer, Emovi), Dr. Michael Dunbar (Principal Investigator & Orthopaedic Surgeon), Dr. Gail Tomblin Murphy (VP Research & Innovation, NSHA)

Dr. Michael Dunbar and the orthopaedic research team, in conjunction with partners Kinduct, Emovi and OrthoMX, are seeking to advance the standard of care, increase treatment options and improve orthopaedic wait times.

NSHA puts a priority on translating research into clinical practice and this project will provide medical staff with enhanced information such that they can make more timely and precise decisions.

Once again, we are drawing a straight line from research and innovation to improved patient outcomes. Nova Scotia Health Authority places a high priority on research and this particular project will advance the standard for patients who need orthopaedic care. We are very pleased to collaborate with industry partners to improve care for Nova Scotians.”
      - Janet Knox, President and CEO, Nova Scotia Health Authority


The technology involved is a three part partnership between Kinduct, Emovi and OrthoMX. Kinduct developed a platform for remote patient monitoring where patients can access information about their care and interact with their healthcare team. Emovi's KneeKG system is a wearable knee assessment device that assesses knee joint functions dynamically. OrthoMX uses the InStride app to track walking patterns. These three parts together will shape the new Mobility Assessment Clinic at the QEII Health Sciences Centre. 

Today we see that meaningful collaboration fosters innovation. With the support of ACOA, our NSHA collaborative research partnership with Kinduct, Emovi and OrthoMX is bringing transformative innovations to patients across Nova Scotia.”
    - Dr. Michael Dunbar, Orthopaedic Surgeon, Endowed Chair of Arthroplasty Outcomes, Queen Elizabeth II Health Sciences Centre
 

Congratulations to Dr. Dunbar and the orthopaedic team!



Tuesday, February 26, 2019

Personalized treatment for bipolar disorder is now an international effort

Dr. Martin Alda
Bipolar disorder knows no borders and now personalized treatment for the disease is following suit. Dr. Martin Alda, Director of the Mood Disorders Program at NSHA & Killam Chair at Dalhousie University, has teamed up with colleagues in Montreal, Paris, Wurzburg and Cagliari on a project granted 834,000Euros (appx $1.25M CDN) in funding from the ERA PerMed Cofund.

The PLOT-BD project aims to shorten the time to remission by studying genetic markers in patients and tailoring treatment on an individual basis. To date, treatments are chosen by trial-and-error taking months or years to become effective. This new approach being studied in Canada, France, Germany and Italy, will look to derive a set of variables associated with treatment outcome and lead to faster recovery.


The proposed solution means shorter times to remission.

The ERAPerMed Cofund has 32 partners from 23 countries and was cofounded by the European Commission in 2018. The PLOT-BD project was announced as one of the first projects to be funded and had to demonstrate the value of interdisciplinary study and transnational collaboration.

Thursday, February 7, 2019

Health Research Boosted by $3.4 Million in Federal Funding

*Note: this post originated on Dalhousie News and is authored by Michele Charlton from Dalhousie.
Seven researchers affiliated with Dalhousie University and the Nova Scotia Health Authority have received $3.4 million in funding from the Government of Canada.
The funding is provided by the Canadian Institutes of Health Research (CIHR) Project Grant Program, which is one of CIHR’s flagship funding programs. These multi-year grants are designed to support researchers at various stages in their careers as they conduct health research and knowledge translation projects that cover the full range of health research topics. Recipients are leaders in their fields and their projects tackle pressing health issues that matter to Canadians.

Highlights of successfully funded researchers


These world-leading researchers will be studying a wide range of topics, including: breast cancer; heart failure and fragility; crossed reflexes and their role in locomotor behaviour; kidney disease; the cost of a healthy diet in Canada; and how lipid synthesis in the nucleus affects a cell’s response to excess fat.
Dr. Turgay Akay
Department of Medical Neuroscience

Sensory control of muscle synergies during walking
From research taking place over the past century, it has been established that locomotor activity is controlled by a set of interconnected spinal interneurons (referred to as “central pattern generator”, or CPG). Sensory feedback has been shown to be important in aiding CPG function, so that the locomotor activity is always appropriate to the environmental need. In addition, walking in the natural environment is typically unpredictably variable, making sensory feedback necessary for functional locomotion.
The capacity to cope with unpredicted changes in the environment during walking gets compromised with advancing age. This leads to increased incidences of injuries related to falls in elderly people adding to costs to health care. This is why understanding the sensory feedback mechanisms that control locomotor activity and how these mechanisms change during aging can help elderly patients to regain the walking ability compromised by disease or aging.
The aim of Dr. Akay’s project is to provide important insights into sensory feedback mechanisms that regulate the locomotor activity and how these mechanisms are affected during aging. He plans to reach this goal by using a combination of mouse genetics, in vivo electrophysiology, and behavioural observations.
Dr. Susan Howlett
Department of Pharmacology, Division of Geriatric Medicine

Why age, sex and frailty matter in heart disease
Heart failure is a serious disease that happens when the heart cannot pump blood very well. It occurs most often in older men and women, but how many years someone has lived is not the whole story. People age at different rates, and those who are aging quickly are said to be frail. This is important, because people frail people are much more likely to develop heart failure regardless of their age.
Dr. Howlett’s research group is discovering how to measure frailty in aging mice, using methods developed in people. They measured many different health problems in individual mice and used this information to estimate a frailty score. Their goal was to find out how age and frailty affect the heart and whether this differs between the sexes, and if these changes make hearts more susceptible to diseases like heart failure.
The work being done by Dr. Howlett will help us understand if treatment of frailty can improve heart function in older people.
Dr. Howlett’s funding comes from a Bridge Grant, which is part of the Project Grant program.
Dr. Margot Latimer (Centre for Pediatric Pain Research, IWK Health Centre, and School of Nursing, Dalhousie University)
Dr. Debbie Martin (School of Health and Human Performance, Dalhousie University)

Dr. Mary McNally (Department of Dental Clinical Sciences and Department of Bioethics, Dalhousie University)
Dr. Sharon Rudderham (Health Director, Eskasoni Community Health Centre)

(Principal Investigators)
Using a co-learning approach to create a collaborative community-led solution to improve indigenous children’s ear and oral wellness and healthy development for school readiness
Indigenous children living in Canada have the highest rates of physical pain-related conditions, but are less likely to be treated for them. Untreated pain, including that associated with poor ear and oral health, have a profound impact on children in terms of their social-emotional wellness, hearing and language development and consequently, their school readiness.
The aim of this project is to create and evaluate a community-led care model to improve ear and oral health outcomes, and enhance school readiness for children (0-5 years) in eight First Nation communities in Wolastoqey and Mi’kma’ki territories.

The funding for this project comes from a Bridge Grant, which is part of the Project Grant program.
Dr. Catherine Mah
School of Health Administration, Healthy Populations Institute

Cost of a healthy diet in Canada
Diet-related diseases are a public health priority. The availability of detailed dietary information from the 2015 Canadian Community Health Survey, which focused on nutrition, offers a chance to assess the actual cost of eating for households based on what they consume.
Dr. Mah will examine dietary intakes and whether they meet recommendations for nutritional adequacy based on healthy eating guidelines. They will also analyze monetary costs associated with healthier eating patterns, and assess whether there are disparities in dietary intakes or dietary costs for Atlantic Canada, a region with the highest burden of diet-related chronic diseases in Canada.
Dr. Mah’s study will offer evidence and potential insights for implementation of dietary guidelines as well as social and fiscal policies to improve the affordability of a healthy diet in Canada.
Dr. Paola Marcato
Department of Pathology, Department of Microbiology & Immunology 
Defining the mechanism of ALDH1A3 in breast cancer for the identification of novel therapeutic targets
To treat breast cancer patients more effectively, we need to better understand why cancer spreads and comes back years later after treatment. Breast tumors are made up of different cancer cells. Among them, cancer stem cell cells (CSCs) have the greatest potential to form new tumors, are very hard to kill and can cause cancer to spread.
Through her research, Dr. Marcato hopes to identify new targets for drugs that kill CSCs and stop the spread of cancer. This should decrease the chance the cancer will return. Her findings will make a major impact in understanding cancer and identifying novel drug targets, and will eventually lead to improved outcomes for patients.
Dr. Neale Ridgway
Department of Pediatrics, Department of Biochemistry and Molecular Biology

How lipid synthesis in the nucleus affects a cell’s response to excess fat
The nucleus is usualy considered as the place where chromosomes store and transmit genetic information from one generation to the next. However, the nucleus is surrounded by a membrane comprised of lipids that keeps it separated from other compartments in the cells, but also allows some connections to these other compartments. It was thought that this membrane connection allowed the nucleus to receive lipids from other compartments instead of making them.
Dr. Ridgway’s research has shown that that nucleus contains enzymes that make lipids, and these lipids are stored within the nucleus. In addition, these stored lipids interact with a protein complex in the nucleus that controls the ability of the cell to respond to stress, such as DNA and oxidative damage.
This study will identify how the production of lipids in the nucleus potentially affects the ability of liver cells to respond to excess fat and prevent its accumulation, which is a cause of disease in the liver and other organs and tissues.
Dr. Karthik Tennankore
Nephrologist, QEII Health Sciences Centre, Nova Scotia Health Authority

Associate Professor, Division of Nephrology, Department of Medicine, Dalhousie University

Frailty and the Kidney Transplant Wait List
Many people with advanced kidney disease will benefit from a kidney transplant. Some people are not eligible because they are considered frail, and have health conditions that put them at a risk of dying before receiving a transplant or high risk of deteriorating health after a transplant. Deciding who is able to receive a transplant involves a detailed evaluation of a person’s health and a review by transplant specialists.
Currently, it is not known how being frail might affect the health of those who are waiting for a kidney transplant. Knowing this information could be helpful in a number of ways.
Dr. Tennankore will be examining what happens to people who are frail and wait listed for a kidney transplant compared with those who are not frail. He hopes that the results of this study may lead to better allocation of kidney transplant organs and a more objective method of evaluating eligibility for the wait list.
Dr. David Waisman
Department of Pathology, and Department of Biochemistry and Molecular Biology 
Significance of S100A10 (p11) in breast cancer tumor progression
Breast cancer is the second leading cause of cancer death in Canadian women. The high incidence of deaths linked to this cancer is due to spreading (metastasis) of the cancer to organs such as lungs and bones.
Cancer cell spreading is assisted by a protein called plasmin which chews other proteins surrounding the tumor cells thereby making the way for the cancer cells to move from the tumor site to distant organs. Plasmin is produced from a blood protein called, plasminogen, by the action of proteins located on the surface of the cancer cells. One such protein, S100A10 (p11), binds plasminogen on the cell surface and speeds up plasmin formation.
In his initial studies, Dr. David Waisman observed that breast tumors and metastasis to the lung are dramatically reduced in mice engineered not to make p11 (p11- null). Moreover, he has shown, by analyzing breast cancer patient tumor samples, that patients with low p11 levels in their breast tissue have a better rate of survival than patients with high p11 levels.
In the current project, Dr. Waisman and his team will investigate how p11 affects tumor growth and metastasis in breast cancer using a well-established breast cancer mouse model that is known to mimic human breast cancer, the PyMT mouse model. They will also investigate if the plasmin generated by p11 is important for the ability of the cancer cells to develop tumors, leave the tumor site and/or grow in other tissues, and if the reduction in tumor growth seen when cancer cells cannot produce p11 is due to decreased cancer cell growth or increased cancer cell death. They will also determine if p11 produced by the other cells in the tumor that support cancer cell development and growth are important or necessary for tumor growth and metastasis.
Identifying the mechanisms by which p11 contributes to tumor growth and metastasis will facilitate the development of new therapies to block tumor growth and metastasis by specifically targeting p11.
More information about the Project Grant program can be found on the CIHR website.

Tuesday, January 8, 2019

2019 is the Year of Partnerships and Innovation

2019 is off to an exciting start for NSHA Research & Innovation. Dr. Steven Beyea and the team at BIOTIC is embarking on a new project that will enable the QEII Health Sciences Centre to be the first in Canada to have a point of care MRI in the emergency department. 

This new equipment is part of a collaboration between BIOTIC and Synaptive and was funded by ACOA ($700k) and the Research Nova Scotia Trust ($1.26M). Synaptive, in addition to being a technology partner, will also provide over $1.3M through in-kind contributions. 

This project highlights Nova Scotia as a centre for research and innovation on the international stage.  Patient outcomes will be studied for 3 years after the equipment is installed in September 2019. The equipment will put the right tools in the hands of clinicians who handle brain injuries. 

Please join us as we congratulate Dr. Beyea and the BIOTIC team. 


At the funding announcement (L to R):Dr. Colin Dodds, Alex Panther, Minister Kousoulis, Janet Knox, Dr. Steven Beyea, MP Andy Fillmore, Dr. Gail Tomblin Murphy



Monday, December 17, 2018

New Frontiers in Research Fund (NFRF)


New Frontiers in Research Fund (NFRF)

After a national consultation process, the Canada Research Coordinating Committee (CRCC) has designed a new fund to help researchers go where they haven’t gone before--at light speed. 

The main objective is to support early career researchers (ECEs) who are working on high-risk, high-reward, interdisciplinary research projects that aren’t necessarily eligible for traditional national funding. “[The NFRF] seeks to inspire highly innovative projects that defy current research paradigms, propose a unique scientific direction, bring disciplines together beyond the traditional disciplinary approaches, and/or use different perspectives to solve existing problems.”
Through this new fund, the federal government will invest $275 million over the next 5 years with the inaugural competition opening today, December 17th, 2018



The deadline for Notice of Intent is January 11, 2019, the application deadline is on February 7, 2019 with funding announced and available in March 2019

Researchers can apply for up to $125,000/year up to 2 years. 

  • Early career researcher = 5 years or less since first academic appointment
  • Not already a grantee or co-grantee of Exploration Award
  • Must be considered an independent researcher at their primary affiliation*
  • Projects must be high-risk and high-reward and may involve any disciplines, thematic areas, approaches or subject areas eligible for funding across the tri-agencies
  • Projects must be interdisciplinary
  • Projects are not eligible if they include any of the following: a focus on the application of existing technology; provide routine analyses; collect data without interpreting underlying mechanisms; provide professional practice or consulting services (contract research); involve the set-up and operational management of an institute, a formal or informal group of researchers (network); and/or are principally associated with the acquisition and maintenance of scientific equipment, curriculum development, organization of a conference or workshop, digitization of a collection, or creation of a database.

The inaugural Exploration competition will involve five selection criteria:
o   Interdiscplinarity
o   Equity, Diversity and inclusion
o   High-Risk
o   High- Reward
o   Feasibility

And have three stages of review (after application submission)
o   Internal review
o   Multidisciplinary review panel
§  Applications weighted (40%- high-risk, 40% high-reward, 20% feasibility)
o   Steering Committee- Canada Research Coordinating Committee (CRCC)
The NFRF is administered by the Tri-agency Institutional Programs Secretariat, which is housed within the Social Sciences and Humanities Research Council (SSHRC), on behalf of Canada’s three research granting agencies: CIHR, NSERC and SSHRC. The new Fund will be using the new Canadian classification standard which is called the Canadian Research and Development Classification 2019 (CRDC).

*Please note: Investigators are required to identify Nova Scotia Health Authority as the administering institution or “Institution Paid” on funding applications for research projects that:
  • are being conducted at NSHA/majority of work taking place at NSHA and
  • involve NSHA patients; which may also
  • utilize or require hiring staff at NSHA
  • utilize NSHA facilities and space
  • involve purchasing supplies or equipment at/through NSHA
  • involve the use of services and payment to NSHA departments or laboratories

For more information or to inform us of your intent to apply for the NFRF, please contact:
Coordinator, Grant Facilitation and Support, NSHA Research Services
Rm. 121-5790 University Ave. Halifax, NS B3H 1V7
Office: 902-473-4841
Cell: 902-240-2785


Did you know we have a calendar full of funding opportunities? Check it out here.